Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Ingrid Garajová

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9302-6896; OpenAlex author ID A5068077224. Sources: OpenAlex.

Their work

Papers
39 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 6 papers · 2023: 4 papers · 2024: 8 papers · 2025: 5 papers · 2026: 5 papers

Papers 39

  1. Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants. First author DOI 10.1016/j.dld.2026.02.020↗
  2. Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey. Co-author DOI 10.1016/j.esmogo.2026.100372↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Longitudinal Circulating Nerve Growth Factor in Pancreatic Ductal Adenocarcinoma: An Exploratory Study of Postoperative Recurrence and First-Line Disease Contr… Co-author DOI 10.3390/biom16101433↗
  5. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  6. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  7. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  8. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  9. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  10. Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.06.007↗
  11. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  12. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  13. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  14. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells. Co-author DOI 10.1186/s13046-023-02879-8↗
  15. NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patien… Last author DOI 10.3389/fphar.2024.1499414↗
  16. Targeting Perineural Invasion in Pancreatic Cancer. Co-author DOI 10.3390/cancers16244260↗
  17. Focus on Pancreatic Cancer Microenvironment. First author DOI 10.3390/curroncol31080316↗
  18. Unraveling the Connection: Pancreatic Cancer Cells and Schwann Cells. Co-author DOI 10.3390/jcm13061785↗
  19. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  20. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  21. Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers. Last author DOI 10.3390/curroncol30070475↗
  22. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. Co-author DOI 10.3390/curroncol30110694↗
  23. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2022.103659↗
  24. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect? Co-author DOI 10.1177/03008916221132589↗
  25. Should patients on levothyroxine therapy be screened for pancreatic cancer? Co-author DOI 10.23750/abm.v93i6.13366↗
  26. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance. Co-author DOI 10.3390/cancers14235793↗
  27. Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Co-author DOI 10.3390/diagnostics12020286↗
  28. It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. Co-author DOI 10.3390/life12070960↗
  29. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  30. The implication of liquid biopsies to predict chemoresistance in pancreatic cancer. Last author DOI 10.20517/cdr.2021.01↗
  31. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Co-author DOI 10.3390/life11080843↗
  32. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000003084↗
  33. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Up… Co-author DOI 10.3390/cancers12113206↗
  34. State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now? Last author DOI 10.21873/anticanres.13484↗
  35. Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer. Co-author DOI 10.2174/1381612825666190119125804↗
  36. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Co-author DOI 10.1007/978-1-4939-3347-1_10↗
  37. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
  38. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step to… Co-author DOI 10.1186/s13148-015-0162-5↗
  39. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Co-author DOI 10.1155/2014/678401↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 22 shared papers, 2014–2026 · strength 4.00
  2. Rita Balsano · 10 shared papers, 2018–2024 · strength 1.58
  3. Annalisa Comandatore · 8 shared papers, 2022–2026 · strength 1.51
  4. Luca Morelli · 8 shared papers, 2022–2026 · strength 1.51
  5. Francesco Leonardi · 7 shared papers, 2021–2024 · strength 1.39
  6. Geert Kazemier M · 7 shared papers, 2016–2026 · strength 0.97
  7. Michele Reni · 5 shared papers, 2021–2026 · strength 0.91
  8. Cindy Neuzillet · 2 shared papers, 2026 · strength 0.71
  9. Andrea Spallanzani · 5 shared papers, 2021–2025 · strength 0.71
  10. Adam Enver Frampton · 6 shared papers, 2014–2024 · strength 0.64
  11. Graziana Digiacomo · 3 shared papers, 2021–2026 · strength 0.63
  12. Andrea Cavazzoni · 3 shared papers, 2021–2026 · strength 0.63
  13. Tessa Y. S. Le Large · 6 shared papers, 2014–2024 · strength 0.61
  14. Francesca Trentini · 2 shared papers, 2024 · strength 0.59
  15. Marina Macchini · 4 shared papers, 2021–2025 · strength 0.55
  16. Mario Scartozzi · 4 shared papers, 2021–2025 · strength 0.55
  17. Giulia Orsi · 4 shared papers, 2021–2025 · strength 0.55
  18. Elisa Giommoni · 4 shared papers, 2021–2025 · strength 0.53
  19. Silvia Bozzarelli · 4 shared papers, 2021–2025 · strength 0.53
  20. Ilario Giovanni Rapposelli · 4 shared papers, 2021–2025 · strength 0.53
  21. Monica Niger · 4 shared papers, 2021–2025 · strength 0.53
  22. Laura L. Meijer · 4 shared papers, 2016–2024 · strength 0.49
  23. Mjriam Capula · 3 shared papers, 2022–2024 · strength 0.49
  24. Lenka N.C. Boyd · 3 shared papers, 2023–2024 · strength 0.49
  25. Sara Lonardi · 3 shared papers, 2023–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.